Spyre Therapeutics (SYRE) Current Deferred Revenue (2016 - 2023)
Spyre Therapeutics (SYRE) posted Current Deferred Revenue of $930000.0 for Q2 2023, up 207.95% on a QoQ basis from $302000.0 in Q1 2023, and down 65.56% year-over-year from $2.7 million in Q2 2022.
Spyre Therapeutics (SYRE) Current Deferred Revenue (2016 - 2023) Analysis & Trends
Spyre Therapeutics' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $930000.0 for Q2 2023.
- Quarterly Current Deferred Revenue fell 65.56% year-over-year to $930000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $930000.0 (down 65.56% YoY) and the FY2022 annual result came in at $517000.0, down 78.08% from the prior year.
- Current Deferred Revenue was $930000.0 for Q2 2023 at Spyre Therapeutics, up from $302000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $19.2 million in Q1 2021 and bottomed at $302000.0 in Q1 2023.
- A 3-year average of $3.9 million and a median of $2.2 million in 2021 frame the typical range for Current Deferred Revenue.
- Peak annual rise in Current Deferred Revenue reached 50.91% in 2022, while the deepest fall reached 89.48% in 2022.
- Spyre Therapeutics' Current Deferred Revenue stood at $2.4 million in 2021, then plunged by 78.08% to $517000.0 in 2022, then jumped by 79.88% to $930000.0 in 2023.
- Business Quant data shows SYRE's Current Deferred Revenue at $930000.0 in Q2 2023, $302000.0 in Q1 2023, and $517000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 930,000.00 |
| Mar 31, 2023 | 302,000.00 |
| Dec 31, 2022 | 517,000.00 |
| Sep 30, 2022 | 505,000.00 |
| Jun 30, 2022 | 2.70 Mn |
| Mar 31, 2022 | 2.10 Mn |
| Dec 31, 2021 | 2.36 Mn |
| Sep 30, 2021 | 4.80 Mn |
| Jun 30, 2021 | 5.50 Mn |
| Mar 31, 2021 | 19.20 Mn |
| Dec 31, 2017 | 20,000.00 |
| Sep 30, 2017 | 50,000.00 |
| Jun 30, 2017 | 71,000.00 |
| Mar 31, 2017 | 51,000.00 |
| Dec 31, 2016 | 71,000.00 |
| Sep 30, 2016 | 181,000.00 |